Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry-Reference-Cited by-同舟云学术

Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry

Published:2017-08-01 Issue:6 Volume:117 Page:775-782
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Jiménez Fonseca Paula, ,Carmona-Bayonas Alberto,Hernández Raquel,Custodio Ana,Cano Juana Maria,Lacalle Alejandra,Echavarria Isabel,Macias Ismael,Mangas Monserrat,Visa Laura,Buxo Elvira,Álvarez Manceñido Felipe,Viudez Antonio,Pericay Carles,Azkarate Aitor,Ramchandani Avinash,López Carlos,Martinez de Castro Eva,Fernández Montes Ana,Longo Federico,Sánchez Bayona Rodrigo,Limón Maria Luisa,Diaz-Serrano Asun,Martin Carnicero Alfonso,Arias David,Cerdà Paula,Rivera Fernando,Vieitez Jose Maria,Sánchez Cánovas Manuel,Garrido M,Gallego J

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2017245.pdf

Reference35 articles.

1. Ajani JA, Rodriquez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S (2009) Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. In: ASCO Annual Meeting Proceedings. J Clin Oncol 27(suppl 15): 4511.

2. Al-Batran S-E, Hofheinz RD, Pauligk C, Kopp H-G, Haag GM, Luley KB, Meiler J, Homann N, Lorenzen S, Schmalenberg H, Probst S, Koenigsmann M, Egger M, Prasnikar N, Caca K, Trojan J, Martens UM, Block A, Fischbach W, Mahlberg R, Clemens M, Illerhaus G, Zirlik K, Behringer DM, Schmiegel W, Pohl M, Heike M, Ronellenfitsch, Schuler M, Bechstein WO, Königsrainer A, Gaiser T, Schirmacher P, Hozaeel W, Reichart A, Goetze TO, Sievert M, Jäger E, Mönig S, Tannapfel A (2016) Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO). Lancet Oncol 17: 1697–1708.

3. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 376: 687–697.

4. Barraclough H, Govindan R (2010) Biostatistics primer: what a clinician ought to know: subgroup analyses. J Thorac Oncol 5: 741–746.

5. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, Koizumi W, Saito H, Yamaguchi K, Takiuchi H, Nasu J, Ohtsu A (2009) Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 10: 1063–1069.

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Retrospective Analysis of the Lauren Classification in the Choice of XELOX or SOX as an Adjuvant Chemotherapy for Gastric Cancer;Current Gene Therapy;2024-04

2. Prognostic factors in gastric cancer patients: a 10-year mono-institutional experience;Frontiers in Surgery;2024-02-01

3. The impact of sex on treatment and outcome in relation to histological subtype in patients with resectable gastric cancer: Results from the randomized CRITICS trial;Journal of Surgical Oncology;2023-12-10

4. Molecular Biology and Clinical Management of Esophageal Adenocarcinoma;Cancers;2023-11-14

5. Effect of preoperative chemotherapy on the histopathological classification of gastric cancer;Gastric Cancer;2023-11-10